MARLENE LENNON: Open Payments
NPI 1023089729 · SAINT HELENA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$954 in 40 payments from 17 companies in 2025. Trend: 2023 $439 · 2024 $1,555 · 2025 $954
Food & beverage: $876Education: $78
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $196 |
| Daiichi Sankyo Inc. | 12 | $190 |
| Merck Sharp & Dohme LLC | 4 | $108 |
| Regeneron Healthcare Solutions, Inc. | 2 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| Janssen Biotech, Inc. | 2 | $47 |
| Regeneron Pharmaceuticals, Inc. | 1 | $38 |
| Genentech USA, Inc. | 1 | $33 |
| Astellas Pharma US Inc | 1 | $30 |
| Lilly USA, LLC | 1 | $28 |
Products named: ENHERTU, KEYTRUDA, LIBTAYO, TAGRISSO, ICLUSIG, LYNOZYFIC, Tecentriq Hybreza, Xospata.
Industry payments across CA — which companies pay providers there.
